Your search matched 43 results
On Friday, the Digital Pharma Innovation Day, Joel Sangerman, Chief Commercial Officer for Click Therapeutics, spoke on the topic of “Digital Therapeutics: Software As Treatments.”
The Syneos Health Podcast: Digital Therapeutics | Perspectives
Our team discusses the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.
In this podcast our team discusses the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.
Digital Therapeutics Grow Up | Perspectives
Digital therapeutics have been hailed as a game-changer for pharma and patients, but are they keeping up with the hype?
Listen to our podcast with Jessica Shull, European Lead for the Digital Therapeutics Alliance, an international non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
Digital therapeutics, or DTx, are distinct from digital health products, and are driven by software programs that can be prescribed to prevent, manage, or treat a medical disorder or disease, as stated by the Digital Therapeutics Alliance.
Inside the Gray Space of Digital Therapeutics | In The Media
Jennifer Kielmeyer, GSW, recaps the DTxDM conference, that brought together more than 200 senior decision-makers from digital therapeutics companies, pharma, investors, payers, and healthcare providers.
At this year’s Digital Medicine & MedTech Showcase (part of Biotech Showcase), a panel of digital therapeutics (DTx) experts illuminated the status and future of their work, moderated by Syneos Health Commercial Solutions Chief Strategy Officer, Baba Shetty.
Where will digital therapeutics or DTx be in five years?
Digital Therapeutics at the Crossroads | Perspectives
Payer perspectives on reimbursement hurdles can help DTx companies map the journey to real-world utilization and market success.
With there being so many different stakeholders, including patients, providers and payers, panelists at the 2019 Digital Medicine & MedTech Showcase pointed to a number of different adoption roadblocks—and successes.
The answer, it seems, is neither yes nor no, and the panelists at 2019 Digital Medicine and MedTech showcase weighed in from a number of different perspectives.
Paving the Way | Perspectives
Is Europe catching up (or pioneering the way) in digital therapeutics?
How DTx Developers Can Satisfy Diverse Stakeholder Needs | Perspectives
All signs point to a breakthrough year for digital therapeutics.
What healthcare stakeholders should think about when it comes to DTx partnerships and how DTx developers can satisfy diverse stakeholder needs.
Recognizing that the impact of multiple sclerosis (MS) goes beyond the conventionally recognized symptoms, Sanofi has announced a new app to support people with the disease—specifically, their mental health.
As the use of artificial intelligence in R&D continues to rise, Novartis takes it even further, equipping its reps with AI that suggests the perfect things to talk about with HCPs.
The Digital & Social Strategy Team recently traveled to Philadelphia to attend the Digital Pharma East conference – the largest event focused exclusively on digital marketing for the life sciences.
Navicor | Agency
Full-service, oncology-focused advertising agency transforming products into brands and patients into survivors.
Patient “opinion leaders” or “thought leaders” are often leveraged as an amplifier of messages around a specific indication on behalf of pharma companies.
Europe | Region
Syneos Health Communications, the network of advertising, public relations and medical communications agencies within Syneos Health(TM) (NASDAQ:SYNH), today announced new digital capabilities and talent.
Holistic healthcare brand Otsuka Pharmaceutical has announced a promising partnership with Science 37, the trailblazing startup out of MIT that’s transforming clinical trials for everyone.
We’re just a few years away from digital therapies taking on traditional medicines on their own turf: clinical trials, formularies, and prescription pads.
Pharmaceutical innovators are getting patients involved in every aspect of drug development, from clinical trial design to commercialization to peer-to-peer support.
This year’s eyeforpharma Barcelona continued notwithstanding COVID-19 constraints, featuring virtual panels of experts across a range of industry fixations.
Last week, pharmaceutical giant Sanofi and healthcare software pioneer Voluntis announced an expansion of their partnership focused on delivering digital therapy in the form of cutting-edge insulin titration tools.
Based on data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, one of the largest-ever clinical trials for depression, a startup called Taliaz is helping physicians pick the right antidepressant therapy off the bat.
For four years, scientists at MIGAL, the Galilee Research Institute, had been working on a COVID-19 vaccine without knowing it.
A recent article from Medical Marketing and Media (MM&M) analyzes what has been on all of our minds in the last 6-9 months: What will pharma’s response be to so many consumer brands crossing over into healthcare?